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Neurobiology of Disease
Complement Receptor 2 Is Expressed in Neural Progenitor
Cells and Regulates Adult Hippocampal Neurogenesis
MaikoMoriyama,1* Takeshi Fukuhara,1* Markus Britschgi,1 Yingbo He,1 Ramya Narasimhan,1 Saul Villeda,1
Hector Molina,2 Brigitte T. Huber,3Mike Holers,4 and TonyWyss-Coray1,5
1Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Palo Alto, California 94305, 2Department of Medicine,
Washington University School of Medicine, St. Louis, Missouri 63110, 3Department of Pathology, Tufts University School of Medicine, Boston,
Massachusetts 02111, 4Departments of Medicine and Immunology, University of Colorado at Denver and Health Sciences Center, Aurora, Colorado 80045,
and 5Rehabilitation, Research, and Development, Veterans Administration Palo Alto Health Care System, Palo Alto, California 94305
Injury and inflammation are potent regulators of adult neurogenesis. As the complement system forms a key immune pathway thatmay
also exert critical functions in neural development and neurodegeneration, we askedwhether complement receptors regulate neurogen-
esis. We discovered that complement receptor 2 (CR2), classically known as a coreceptor of the B-lymphocyte antigen receptor, is
expressed in adult neural progenitor cells (NPCs) of the dentate gyrus. Two of its ligands, C3d and interferon- (IFN-), inhibited
proliferation of wild-type NPCs but not NPCs derived frommice lacking Cr2 (Cr2/), indicating functional Cr2 expression. Young and
old Cr2/ mice exhibited prominent increases in basal neurogenesis compared with wild-type littermates, whereas intracerebral
injection of C3d resulted in fewer proliferating neuroblasts in wild-type than in Cr2/mice.We conclude that Cr2 regulates hippocam-
pal neurogenesis and propose that increased C3d and IFN- production associated with brain injury or viral infections may inhibit
neurogenesis.
Introduction
The complement system is an important regulator of immune
responses. Complement proteins can attract and activate various
immune cells, amplify adaptive immune responses, promote
phagocytosis, facilitate complement-mediated cytolysis by the
membrane attack complex, and regulate cell proliferation and
differentiation. Complement C3 is the central protein of the
complement cascade, mediating its functions through various
proteolytic fragments that bind to distinct complement receptors
(CR) (Holers, 1996; Sahu and Lambris, 2001). Different C3 frag-
ments can bind to CR1 (also known as CD35), CR2 (CD21), CR3
(CD11b/CD18), CR4 (CD11c/CD18), as well as C3a receptor
(C3aR) (Holers, 1996). Most of these receptors and their func-
tions are conserved between mouse and human except CD35,
which is an alternative splice product of the Cr2 gene in mouse
but encoded by a separate gene in humans (Jacobson and Weis,
2008).
In the brain, complement can be produced by astrocytes, mi-
croglia, and neurons, and production is increased in brain injury
and neurodegeneration (D’Ambrosio et al., 2001; Gasque, 2004).
Genetic studies in mouse models have illustrated the complex
function complement has in the brain. For example, overproduc-
tion of the rodent complement C3 inhibitor Crry (Wyss-Coray et
al., 2002) or lack of C3 (Maier et al., 2008) led to increased accu-
mulation of -amyloid in mouse models for Alzheimer’s disease
(AD), whereas lack of C1q reduced neurodegeneration in an-
other AD mouse model (Fonseca et al., 2004). C1q appears to
have a role in synaptic pruning during development (Stevens et
al., 2007), and chronic increases of C1q observed in many neu-
rodegenerative diseases have been postulated to promote synapse
elimination. Interestingly, complement C3 and C3aR deficiency
were associated with reduced neurogenesis in unmanipulated
brains and after stroke (Rahpeymai et al., 2006), supporting a role
for C3a, a potent inflammatory mediator, in the regulation of
adult neurogenesis.
The adult mammalian brain can form new neurons in the
subventricular zone of the lateral ventricles and the subgranular
zone of the dentate gyrus in the hippocampus. Newly born neu-
rons can integrate into functional circuits in the olfactory bulb or
hippocampus, respectively. While the consequences of this pro-
cess, particularly in the human brain, are unclear (Leuner et al.,
2006; Zhao et al., 2008), hippocampal neurogenesis is required in
forming certain types of memories in mice (Dupret et al., 2008;
Zhang et al., 2008). Interestingly, injury stimulates (Dash et al.,
2001) whereas inflammation inhibits neurogenesis (Monje et al.,
2002, 2003; Ekdahl et al., 2003). Basal and injury-induced pro-
duction of new hippocampal neurons dramatically decreases
with age, as does the ability of neural progenitor cells (NPCs) to
proliferate (Kuhn et al., 1996; Yagita et al., 2001; Jin et al., 2004).
This may be the result of both declining levels of mitogens,
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growth, and survival factors (Anderson et al., 2002; Shetty et al.,
2004) and increased abundance of inhibitory signals (Buckwalter
et al., 2006), but more work is needed to understand the molec-
ular mechanisms regulating adult neurogenesis. Because the
complement system has broad functions in inflammation and
cell homeostasis, we asked whether complement receptors may
regulate neurogenesis.
Materials andMethods
Mice.Mice deficient in theCr2 gene (Cr2/) were obtained fromDr.H.
Molina (Washington University, St. Louis, MO) (Molina et al., 1996).
Mice deficient in the Cr3 gene (Cr3/) were obtained from T.Mayadas
(Harvard Medical School, Boston, MA) (Coxon et al., 1996). Human
CR2/CD21 transgenic mice harboring a bacterial artificial chromosome
(BAC; hCD21 BAC; RP11-35C1; mouse line 38) express hCR2 under
control of its natural human regulatory sequences (Hsiao et al., 2006).
Cr2-Cremice [B6.Cg-Tg(Cr2-cre)3Cgn/J; stock number 006368] harbor
a transgene consisting of a cre recombinase expression cassette inserted
into a BAC containing the mouse Cr2 locus (Kraus et al., 2004) and were
obtained from The Jackson Laboratory. We used two lines of Cre re-
porter mice: a double-fluorescent reporter mouse [B6.129(Cg)-
Gt(ROSA)26Sortm4(ACTB-tdTomato,-EGFP)Luo/J; stock number 007676],
which harbors a chicken actin core promoter with a cytomegalovirus
enhancer driving membrane-targeted tandem dimer Tomato (mT)-
polyA fragment flanked by loxP sites upstream of enhanced green fluo-
rescent protein (EGFP) inserted into the ROSA26 locus (Muzumdar et
al., 2007), or a reportermouse [B6. Cg-Gt(ROSA)26Sortm1(rtTA, EGFP) Nagy/J;
stock number 005670[, which harbors a PGK-neo-polyA fragment
flanked by loxP sites upstream of rtTA and EGFP inserted into the
ROSA26 locus (Belteki et al., 2005). Both mouse lines were obtained
from The Jackson Laboratory and bred on an inbred C57BL/6J genetic
background using wild-type mice from The Jackson Laboratory. We
used male and female mice in all experiments and did not observe any
significant differences in the measurements reported herein. All animal
care and use was in accordance with institutional guidelines and ap-
proved by the Veterans Administration Palo Alto Committee on Animal
Research.
Immunohistochemistry. Immunostaining of mouse brain tissue was
performed as described previously (Buckwalter et al., 2006). Briefly,
brains of mice were immersed in 4% paraformaldehyde (PFA) overnight
at 4°C, sunk through sucrose, and sectioned to 40m in thickness with a
cryomicrotome. For 3,3-diaminobenzidine (DAB) staining, sections
were incubated with primary antibody rat anti-bromodeoxyuridine
(BrdU; 0.4 g/ml; Abcam) or goat anti-doublecortin (Dcx) (0.4 g/ml;
Santa Cruz Biotechnology) overnight at 4°C, rinsed, and incubated with
biotinylated rabbit anti-rat (1g/ml, vector) or rabbit anti-goat antibody
(3 g/ml, (Vector Laboratories) followed by ABC labeling (Vector Lab-
oratories) and development with DAB (Sigma). For BrdU labeling, brain
sections were pretreated with 2N HCl at 37°C for 30 min before incuba-
tion with a primary antibody. For multilabel immunofluorescence of
BrdU and cell-type-specific markers, sections were incubated overnight
with rat anti-BrdU, rinsed, and incubated for 1 h with donkey anti-rat
antibody (2.5 g/ml; Vector Laboratories) before they were stained with
one or two of the following antibodies: goat anti-Dcx, mouse anti-GFAP
(1:1000; Millipore), and mouse anti-NeuN (1.0 g/ml; Millipore). To
characterize green fluorescent protein (GFP)-expressing cells in the
Figure 1. A–D, Cr2-cre-controlled EGFP reporter gene is expressed in NPCs of the subgranular zone. Representative images of EGFP-expressing cells in the spleen (A), the hippocampus (B), and
the dentate gyrus (C, D) of a 2-month-old double-transgenic Cr2-cre;mT/mG reporter mouse. Ubiquitously expressed, membrane-targeted tandem dimmer Tomato is replaced by membrane-
targeted EGFP (mG) after cre-dependent recombination.A, Representative fluorescentmicroscopy images of the spleen labeledwith an anti-Cr2 (CR2/CD35, clone 7E9) antibody (red), EGFP (green),
or Tomato (blue).B, Representative fluorescentmicroscopy images of the hippocampus stainedwith anti-Sox2 (red), EGFP (green), and Tomato (blue) from a Cr2-cre;mT/mG reportermouse at low
magnification. Themerged image shows hippocampal cells expressing EGFP. C, High-magnification images of the boxed area in B (merged image) and three-dimensional reconstruction of a stack
of deconvoluted confocal images. D, Orthogonal view of confocal microscopy images showing colocalization of membrane-targeted EGFP and Sox2 (arrow), which is an NPC marker in the
subgranular zone. Scale bars, 300m.
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spleen and the dentate gyrus ofmT/mGmice, anti-Cr2 (clone 7E9, 1:100;
BioLegend) and anti-Sox2 (clone Y-17, 1:500; Santa Cruz Biotechnol-
ogy) were used. Primary antibody staining was detected with secondary
antibodies Cy3 donkey anti-rat (1:500; Jackson ImmunoResearch), Al-
exa 488 donkey anti-goat (100 g/ml; Invitrogen), Alexa 546 donkey
anti-mouse (100 g/ml; Invitrogen), Alexa 488 donkey anti-mouse (100
g/ml; Invitrogen), or Alexa 488 donkey anti-rabbit (100 g/ml; Invit-
rogen). Fluorescence images were obtained using a confocal-lasermicro-
scope (LSM 510 meta Pascal; Carl Zeiss MicroImaging). Volocity
software (PerkinElmer) was used for three-dimensional reconstruction
with a coarse algorithm and deconvolution of Z-stack fluorescence
images.
Quantification of Dcx-positive cells. To quantify Dcx staining in
8-week-old mice, MetaMorph imaging software (version 6.1r1; Molecu-
lar Devices) was used. The percentage of pixels above background stain-
ing within a region drawn around the dentate granule cell layer and
subgranular zone was quantified. This method was used because the cell
density was too high to count the cells in these 40-m-thick sections
using light microscopy. In all other mice, Dcx-positive cells in the same
region were counted in every 12th coronal section through the hip-
pocampus, and the total number of Dcx cells for each section was
estimated by multiplying the number of cells counted by 12.
BrdU labeling and quantification of BrdU-positive cells. BrdU (50 mg/
kg) was injected intraperitoneally into 8-week-old mice once per day for
6 d, and mice were killed 1 d (short-term labeling) (see Fig. 5) or 28 d
(long-term labeling) (see Fig. 6) later. To estimate the total number of
BrdU-positive cells in the brain, we performedDAB staining for BrdUon
every sixth hemibrain section. BrdU cells in the granule cell and sub-
granular cell layer of the dentate gyrus in hemibrain were counted
blinded with respect to genotype. The total number of BrdU cells in
these hippocampal regions was then estimated
by multiplying the number of cells counted by
12. Confocal microscopy was used to examine
50–100 BrdU-positive cells from each mouse
for each stain to determine whether they cola-
beled with Dcx, NeuN, or both, or with GFAP.
The number of double- or triple-positive cells
was expressed as a percentage of BrdU-positive
cells.
Cell culture.MouseNPCswere isolated from
forebrains or hippocampi of postnatal day 0
(P0) to P3 mice and cultured as described pre-
viously (Reynolds and Rietze, 2005). Briefly,
brains or hippocampi were dissected and incu-
bated in DMEM containing 2.5 U/ml papain
(Worthington Biochemicals), 250 U/ml DNa-
seI (Worthington Biochemicals), and 1 U/ml
dispase II (Roche Diagnostics) at 37°C for 45
min. Undigested pieces of tissue were removed
by centrifugation at 500  g for 5 min, and
NPCs were isolated using 65% Percoll (GE
Healthcare) in DMEMwith 10% FCS. Cellular
pellets were resuspended in DMEM/F-12 con-
taining 5 mM HEPES buffer, 0.6% glucose, 3
mM sodium bicarbonate, 2mM L-glutamine, 20
g/ml insulin, 60 M putrescine, 100 M apo-
transferrin, 6.3 ng/ml progesterone, 5.2 ng/ml
sodium selenite, 2g/ml heparin, 20 ng/ml ep-
idermal growth factor (EGF), and 10 ng/ml
basic FGF (bFGF), counted, and plated in un-
coated plates at 1  106 cells/ml. To prepare
neurospheres from hippocampi, the Percoll
purification stepwas foundnot to be necessary,
and digested tissues were directly cultured in
Neurobasal-A medium (Invitrogen) supple-
mented with B27 (Invitrogen), Glutamax (In-
vitrogen), and the growth factors EGF (20 ng/
ml; PeproTech) and bFGF (20 ng/ml; PeproTech).
To passage cells, neurospheres were harvested
by centrifugation (500 g for 5 min) and dis-
sociated in Hanks-based cell dissociation buffer (Invitrogen). Rat NPCs
were cultured as described previously (Monje et al., 2003). Briefly, cells
were grown in DMEM/F-12 supplemented with N2 supplement and 20
ng/ml bFGF (PeproTech).
Reverse transcription-PCR and quantitative PCR analysis. Total RNA
was extracted using Trizol reagent (Invitrogen) and treated with the
TURBODNA-free kit (Applied Biosystems) to digest DNA. Twomicro-
grams of DNase-treated RNA samples were subjected to first-strand
cDNA synthesis using oligo-dT primers supplied by the Taqman reverse
transcription reagents kit (Applied Biosystems) by following the instruc-
tion manual. Primers used in this study are listed in supplemental Table
1 (available at www.jneurosci.org as supplemental material). For reverse
transcription-PCR (RT-PCR), glyceraldehyde 3-phosphate dehydroge-
nase(GAPDH) and GFP transcripts were amplified using ExTaq poly-
merase (Takara). Cr2 and  actin transcripts were amplified using
AmlpiTaqGold (Applied Biosystems) polymerase. For quantitative PCR
(qPCR), gene-specific primer sets designed by either PrimerBank (http://
pga.mgh.harvard.edu/primerbank/index.html) or RTPrimerDB (http://
medgen.ugent.be/rtprimerdb/)wereverified toproducesingleamplification
products by gel electrophoresis. Using SYBR Green PCR Master mix
(Applied Biosystems), reaction productswere quantified andnormalized
to standard curves generated separately for each transcript from mRNA
obtained fromA20 cells (R 2 0.9873 for Cr2,R 2 0.9835 forGAPDH).
SDS2.3 software from the ABI9700HT system (Applied Biosystems) was
used to process data.
Neurosphere assay. To assess the number of neurospheres, 1  103
mouse NPCs at passage 5 were seeded per well in 96-well plates and
incubated for 48 h at 37°C in the presence or absence of CR2 ligands and
various antibodies. The total number of neurospheres in each well with
Figure 2. Cr2-controlled transcripts are expressed in NPCs. Total RNAwas extracted from primarymouse NPCs, splenocytes, or
thehumanB-cell lymphoma cell line LKPLLL and reverse transcribed, and segments of EGFP,mouse, or humanCR2were amplified.
cDNA was synthesized with oligo-dT primers in the presence (RT) or absence (RT) of reverse transcriptase from total RNA
extracts. -Actin or GAPDH served as a loading controls. A, EGFP transcripts were detected in NPCs isolated from Cr2-Cre mice
crossed with ROSA-EGFP reporter mice but not in wild-type littermate control mice. B, Human CR2 transcripts were detected in
transgenic NPCs from hCD21-BAC;Cr2/ mice (hCR2-Tg) and in human B-cells (LKP-LLL) but not in nontransgenic NPCs or
wild-type splenocytes. C, Endogenous mouse Cr2 transcripts were detected in splenocytes or NPCs from wild-type (WT) mice but
not inNPCsderived from Cr2 knock-out (Cr2/) littermate controls. non-Tg,Nontransgenic.D, Quantificationof endogenous Cr2
transcripts by qPCR. Sample cDNAs of spleen, theB-cell lineA20, primaryNPCs derived fromP1C57BL/6wild-type or FVBwild-type
mice, primary astrocytes, or themicroglial cell line BV2. Samples were run in quadruplicates, and transcript levels were estimated
basedon standard curvesgenerated for Cr2orGAPDH.Relative Cr2 transcript levels arepresentedas apercentageof levels detected
in spleen (100%). Bars are mean SEM.
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diameters50 mwere counted. Neurosphere size was evaluated using
MetaMorph imaging software (version 6.1r1; Molecular Devices). The
cell number per dissociated sphere was analyzed from the same cultures
using a standard Neubauer counting chamber. Cells were treated with
the following proteins or antibodies: purified humanC3 and humanC3d
(Complement Technology); recombinant mouse interferon A (IFN;
PBL Interferon Source); monoclonal rat anti-mouse CD35/CR2 anti-
body (clone 7G6; BD Biosciences); polyclonal rabbit anti-human C3d
(Dako); and biotin rat IgG2a isotype control antibody (BioLegend).
Rat NPC line proliferation assay. A total of 1  104 rat NPCs were
incubated with C3 or C3d at the indicated concentration at 37°C for 48 h
before cell counting. A rabbit antibody against human C3d (1:1000;
Dako) was used for blocking C3d.
Stereotaxic injections andBrdU labeling.Purified humanC3d (0.5g in
0.5l) was injected stereotaxically into the right side of the dentate gyrus,
and an equal amount of saline was injected into the left side (1.75 mm
posterior, 0.75 mm lateral, 1.7 mm ventral from bregma). After mice
gained consciousness from surgery, 50 mg/kg BrdU was injected intra-
peritoneally once and then again daily for 5 d until mice were killed on
day 7. Brains were removed, immersed in 4%PFA overnight at 4°C, sunk
through sucrose, and sectioned to 40 m in thickness with a cryomi-
crotome. Five sections close to the injection site were then stained with
antibodies against BrdU and Dcx as described above. The number of
BrdU/Dcx double-positive cells was counted using confocal micros-
copy on the C3d- or saline-injected sides on the one section most prox-
imal to the injection site per mouse, and the ratio of double-labeled cells
between C3d- and saline-injected sides was calculated.
Statistical analysis. All immunohistochemical experiments were ana-
lyzed by an investigator blinded to genotype or age. Values are presented
as mean SEM. Differences among groups were analyzed using t test or
one-way ANOVA with the Scheffé’s post hoc test. p values 0.05 were
considered to be significant. Analyses were done using Statview software.
Results
Cr2 and related adaptor genes are expressed in NPCs
Injury and inflammation are potent regulators of adult neuro-
genesis (Dash et al., 2001; Monje et al., 2002, 2003; Ekdahl et al.,
2003). To determinewhether complement factors are involved in
this process, we asked whether complement receptors are ex-
pressed in NPCs. Whereas CR3 (CD11b/CD18) and CR4
(CD11c/CD18) are accepted markers for the myeloid lineage,
expression of the Cr2 gene product CR2, which is involved in
multiple stages of B-lymphocyte differentiation and proliferation
(Tolnay and Tsokos, 1998; Carroll, 2004), has not been studied in
neurogenesis. To track Cr2 gene expression in vivo, we crossed
Cr2-cre transgenic mice [B6.Cg-Tg(Cr2-cre)3Cgn/J] (Kraus et
al., 2004), which harbor cre recombinase inserted into a mouse
Cr2 BAC clone, with ROSA26-Actin promoter-loxP-mT-pA-
loxP-mEGFP-pA reporter mice (herein called mT/mG mice)
(Muzumdar et al., 2007). In double-transgenicmice, cre-induced
recombination in Cr2-expressing cells leads to excision of the
gene encoding for membrane-targeted tandem dimer Tomato
and a stop sequence resulting, in turn, in expression of
membrane-targeted EGFP. Thus, every cell in this mouse either
expresses Tomato or EGFP. To validate the Cr2-driven Cre re-
porter system, we stained spleen tissue sections with the anti-Cr2
antibody 7E9 and compared it with Cr2-cre-induced EGFP pro-
tein expression in 2-month-old Cr2-cre;mT/mG reporter mice.
We observed that all EGFP-expressing cells also labeled with the
Cr2 antibody (Fig. 1A). In the brain, EGFP-positive cells were
found throughout the hippocampus (Fig. 1B), suggesting that
these cells are still expressing CR2 or that they descended from
CR2-expressing precursors. Higher-power confocal images
showed that many of the cells in the subgranular zone of the
dentate gyrus also expressed Sox2, consistent with characteristics
of NPCs (Fig. 1C, D; supplemental Video 1, available at
www.jneurosci.org as supplemental material).
Because none of the available Cr2 antibodies produced spe-
cific staining on brain sections if Cr2 knock-out mice were used
as a control (supplemental Table 2, available at www.jneurosci.
org as supplemental material), we measured Cr2 mRNA in brain
tissue and cells. In support of Cr2 promoter activity in NPCs,
EGFP mRNA was expressed in freshly isolated neonatal NPCs
from Cr2-cre;ROSA26-GFP reporter mice that harbor the
ROSA26-loxP-stop-loxP-rtTA-IRES-EGFP reporter construct
(Fig. 2A). Additional evidence that the CR2 promoter is active in
NPCs was obtained from “humanized” CR2 transgenic mice in
which an artificial bacterial chromosome containing the human
CR2 locus (which does not contain the independent CD35 gene)
leads to human CR2 (hCD21) expression under control of the
human promoter, for example, in B-cells (Hsiao et al., 2006). In
addition, the mice were crossed onto the Cr2/ background,
essentially replacing mouse Cr2 with human CR2. Notably,
CD35 (endogenous mouse and human) is lacking in these mice.
Figure3. CR2 ligands reduce thenumber of neurospheres in cultures of primarymouseNPCs
and a rat NPC line. A, Primary mouse NPCs were isolated from hippocampi of newly born
Cr2/ (open bars) andwild-type (WT; filled bars)mice, and established cultures at passage 5
were treatedwith purified human C3d (10g/ml) in the presence or absence of anti-CR2/CD35
antibody 7G6, which blocks ligand binding, with IFN- (1000 U/ml), or with vehicle or an
isotype control antibody for 48 h. The average number of neurospheres50 m per field
(average of 3 fields at 20magnification) from triplicate cultures are shown. Note the inhibi-
tory effect of CR2 ligands inWT but not in Cr2/NPCs.B, Rat NPCs (1 10 4) were seeded in
six-well plates and treated with purified human C3 or C3d at the indicated concentrations or
with C3d together with a C3d-neutralizing antibody or a control isotype antibody. The cell
number was counted after 48 h. Bars represent mean SEM from triplicate cultures from
one of three representative experiments. *p 0.05, ***p 0.001, by one-way ANOVA
and Scheffé’s post hoc test.
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We observed that NPCs from these hCD21-BAC;Cr2/ mice
expressed human CR2 mRNA, whereas NPCs from nontrans-
genic mice did not (Fig. 2B). These findings strongly suggest that
NPCs express CR2. Last, neonatal wild-type primary mouse
NPCs expressed Cr2 mRNA by RT-PCR, whereas Cr2/ NPCs
did not (Fig. 2C). To assess relative levels of Cr2 expression, we
compared transcript levels inNPCswith those in lymphoid tissue
and other CNS cells using qPCR. Although NPCs isolated from
C57BL/6 or FVB mouse strains expressed 1% of Cr2 mRNA
compared with spleen or B-cell line A20, they expressed three to
four times the amount detected in primary astrocytes (Fig. 2D).
Microglia showed no detectable Cr2 mRNA (Fig. 2D). Because
CD35 and CR2 are splice products encoded by the same gene in
mice (i.e., Cr2) and differ from each other only by several iden-
tical so-called short consensus repeats (Carroll, 2004), we were
not able to amplify specific transcripts discerning the splice
variants.
CR2 is a key module of the B-cell antigen receptor complex
together with CD19, CD81, and CD225, and therefore we asked
whether these other components are also expressed in NPCs.
Indeed, we were able to detect mRNAs encoding for all three
components (supplemental Fig. S1, avail-
able at www.jneurosci.org as supplemen-
tal material), which are involved, in part,
in B-cell receptor signal transduction. To-
gether, these findings show Cr2 is ex-
pressed in mouse NPCs and raise the
question whether it is functionally active.
CR2 ligands inhibit NPC proliferation
In B-cells, CR2 together with several
adaptor proteins functions as the corecep-
tor for membrane-bound Igs (i.e., the
B-cell receptor) by binding antigens coated
with the complement adjuvant C3d, thus
playing an important role in the activation
and proliferation of B-cells (Tolnay and
Tsokos, 1998; Carroll, 2004). To deter-
mine the functionality of CR2 in NPCs,
we cultured primary postnatal NPCs de-
rived from hippocampi or the entire fore-
brain from Cr2/ mice (Molina et al.,
1996) and wild-type littermate controls,
as well as previously characterized rat
NPC lines (Monje et al., 2003) in the pres-
ence and absence of CR2 ligands. We first
tested the effect of human C3d, which is a
functional ligandof themouseCR2 recep-
tor (Molina et al., 1991). In the absence of
ligands, there was no consistent difference
in the number or size of neurospheres at
various passages between cultures derived
from Cr2/ mice or wild-type litter-
mates (supplemental Fig. S2, available at
www.jneurosci.org as supplemental ma-
terial), and there were no apparent mor-
phological differences in cell size or
shape (data not shown). Treatment of
hippocampal-derived wild-type primary
mouse NPCs with purified human C3d
reduced neurosphere number by one-
third but had no effect on Cr2/ NPCs
(Fig. 3A). Consistent with these findings,
C3d also reduced proliferation in the rat NPC line, whereas C3d
incubated with C3d-neutralizing antibody or intact C3 had no
effect on cell proliferation (Fig. 3B). Complement C3d or C3 did
not induce overt cell death as no significant increase in lactate
dehydrogenase could be measured in culture supernatants from
C3d- or C3-treated compared with untreated NPCs (data not
shown). The cytokine IFN- has recently been shown to signal
through the same domains of human CR2 as C3d and to bind to
it with similar affinity (Asokan et al., 2006). Consistentwith being
a ligand for CR2, IFN- significantly inhibited proliferation in
wild-type but not Cr2/ primary mouse NPCs (Fig. 3A). Fur-
thermore, the decrease in proliferation seen in wild-type primary
mouse NPCs was reversed by the addition of antibody 7G6,
which blocks ligand binding to CR2 (Martin et al., 1991), further
supporting that C3d and IFN- inhibit NPC proliferation in our
cell-culture system by binding to CR2. In line with these results,
neurosphere number and the number of cells per neurospheres
were reduced after C3d or IFN- treatment in wild-type NPCs
derived from entire mouse forebrains but not in Cr2/ NPCs
(supplemental Fig. S3, available at www.jneurosci.org as supple-
mental material). In summary, these findings demonstrate the
Figure4. Cr2/mice exhibit increased neurogenesis. Brains of Cr2/mice andwild-type littermate controls at 8weeks or
5–7months of age or littermates froma cross of Cr2/with Cr3/mice at 13–16months of agewere analyzed for expression
of Dcx, amarker of proliferating neuroblasts and immature neurons, in the dentate gyrus. A, Representative images depicting the
dentate gyrus from 40m brain sections of 8-week-old and 13- to 16-month-old Cr2/ and wild-type (WT) mice immuno-
stained with anti-Dcx antibodies and developed with immunoperoxidase and diaminobenzidine. Scale bars, 200 m. B–D,
Quantitative analysis of Dcx immunostaining assessed as the relative area of the dentate gyrus occupied by immunoreactive label
(B) or number of positive cells per dentate gyrus per mouse (C, D) at the indicated ages. Note the prominent increase in Dcx
neuroblasts in Cr2/ and Cr2/3/ compared with Cr3/ or wild-type mice. Bars represent mean SEM; n 4–8 mice
per group. *p 0.05; **p 0.01; ***p 0.001, by t test (B, C) or one-way ANOVA and Scheffé’s post hoc test (D).
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functional expression of Cr2 in cultured
mouse and rat NPCs and show that CR2
ligands inhibit NPC proliferation.
Lack of Cr2 in mice results in increased
basal neurogenesis
To investigate whether CR2/CD35 have a
role in adult neurogenesis in vivo, we as-
sessed expression of Dcx, amarker of pro-
liferating neuroblasts and immature
neurons, in Cr2/ and wild-type litter-
mates. We also analyzed neurogenesis in
mice deficient in Cr3, a major phagocyte
receptor restricted to microglia and mac-
rophages in the brain, or in crosses result-
ing from these mice and lacking both Cr2
and Cr3. Lack of Cr2 resulted in a twofold
increase in Dcx immunoreactivity in the
dentate gyrus at 8 weeks and 5–7 months
of age (Fig. 4A–C) and an almost three-
fold increase in the number of Dcx cells
in 13- to 16-month-old Cr2/ mice
compared with wild-type controls (Fig.
4A,D). In contrast, littermate mice defi-
cient in Cr3 showed no changes in the
number ofDcx-expressing cells compared
with wild-type controls (Fig. 4D). Mice
lacking Cr2 and Cr3 showed equal in-
creases in Dcx-expressing cells as Cr2/
mice (Fig. 4D).
To determine whether lack of Cr2 led
to an increase in proliferation in the hip-
pocampus, the nucleotide analog BrdU
was injected into mice for 6 d, and the
commitment of newly generated cells was
evaluated 1 d later. NPCs in the subgranu-
lar zone of the dentate gyrus are capable of
differentiating into either the neuronal or
glial lineage. Whereas the total number of
BrdU cells in the dentate gyrus was not
significantly different between wild-type
and Cr2/mice in this short-term label-
ing paradigm (Fig. 5A), the number of
BrdU/Dcx cells was slightly but signif-
icantly increased inCr2/mice (Fig. 5B–
D). As expected, over this short time only
few dividing cells acquired a NeuN-
positive phenotype, and this was not
changed by the lack of Cr2. The commit-
ment of NPCs to the glial lineage was as-
sessed using GFAP as a marker for astrocytes. No significant
difference was observed in BrdU/GFAP cells between wild-
type and Cr2/ mice after short-term labeling with BrdU (Fig.
5B–D). Nevertheless, out of all dividing cells, the percentage of
GFAP-expressing and other non-neuronal dividing cells was re-
duced from 32.6 to 20.8% in Cr2/mice compared with wild-
type littermate controls, whereas the number of cells in the
neuronal lineage increased from 67.4 to 79.2% (Fig. 5D).
To determine whether the increase in Dcx cells observed in
Cr2/ mice is the result of changes in the maturation and sur-
vival of newly generated immature neurons, we analyzed the
number of label-retaining neurons 28 d after BrdU injection. In
this long-term labeling paradigm, Cr2/mice at 8 weeks of age
(Fig. 6A) and, more profoundly, at 5–7 months of age (Fig. 6A)
had significantly more BrdU cells overall than wild-type mice,
and there were more mature BrdU/NeuN neurons in Cr2/
mice at 8 weeks of age (Fig. 6B,C).
Treatment with CR2 ligand reduces the number of
proliferating neuroblasts in vivo
To determine whether Cr2 encodes a functional gene product in
NPCs and CR2/CD35 signaling affects neurogenesis in vivo, we
stereotaxically injected C3d into the right dentate gyrus of wild-
type or Cr2/mice. Saline was injected as a control into the left
dentate gyrus, and BrdU was given for 6 d intraperitoneally until
the mice were killed the next day. Injection of C3d resulted, on
Figure 5. Differentiation of newly generated BrdU cells into the neuronal lineage is increased in Cr2/ mice. After a
short-term labeling protocol, 8-week-old Cr2/ mice and wild-type (WT) littermate controls (n 5 mice per group) were
injected daily with BrdU for 6 d and killed 1 d later. A, The total number of BrdU cells per dentate gyrus was similar in wild-type
and Cr2/mice. n.s., Nonsignificant. B, Representative confocal microscopy images from the subgranular zone of the dentate
gyrus of brain sections immunostained for BrdU (red) in combinationwithDcx (green) andNeuN (blue; BrdU/Dcx/NeuN) or
GFAP (green; BrdU/GFAP). Scale bars, 20 m. C, Relative number of BrdU/Dcx of all BrdU cells was increased in
Cr2/mice, whereas BrdU/GFAP cells were unchanged. Bars representmean SEM. *p 0.05, by one-way ANOVA and
Scheffé’s post hoc tests. D, Cell fate of newly generated neural cells 1 d after BrdU labeling of all BrdU-positive cells (each pie
represents 100% of BrdU cells).
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average, in a 35% decrease in the number of BrdU/Dcx cells in
the ipsilateral compared with the saline-injected side. Consistent
with cell culture data, C3d had no effect in Cr2/mice (Fig. 7).
These findings further corroborate the cell-culture studies sug-
gesting that CR2/CD35 is functionally expressed in the hip-
pocampus and can modulate adult neurogenesis in vivo.
Discussion
The complement system is best known for its critical functions in
the immune system, but a growing number of studies have tied
complement factors genetically to neurodegenerative diseases in
humans and mice (Wyss-Coray et al., 2002; Haines et al., 2005;
Klein et al., 2005; Maier et al., 2008). Most recently, the human
CR1 locus was linked to AD in a large genome-wide association
study (Lambert et al., 2009), although the biological role of CR1
in that disease, or in the brain in general, is unknown. Here we
describe that Cr2, best known for encoding a key component of
the B-cell receptor complex, is functionally expressed in NPCs.
We demonstrate that Cr2/mice exhibit increased numbers of
immature and mature neurons in the hippocampus, implicating
Cr2 in the maintenance of adult neurogenesis. Conversely, C3d
and IFN-, two independent ligands of human CR2/CD21, in-
hibit NPC proliferation in cell culture, and injection of C3d
into the dentate gyrus reduces the number of immature neu-
roblasts in vivo.
Our findings add C3d and IFN- to a growing number of
immune molecules and inflammatory proteins that regulate
adult neurogenesis in rodents. For example, interleukin-1 (IL-
1) (Koo and Duman, 2008), IL-6 (Monje et al., 2003), tumor
necrosis factor- (Iosif et al., 2006), and transforming growth
factor- (Buckwalter et al., 2006;Wachs et al., 2006) inhibit neu-
rogenesis. It is unclear whether these factors are merely sufficient
to inhibit adult neurogenesis when increased or whether they are
also required to exert a certain negative signal to maintain ho-
meostatic levels of neurogenesis. On the other hand, immune
regulatory factors such as IL-6, leukemia inhibitory factor, or
ciliary neurotrophic factor that signal through gp130 can stimu-
late neural stem cell proliferation or maintain stem cell fate
(Shimazaki et al., 2001; Bauer and Patterson, 2006). The relative
importance of these proteins needs to be determined as it is un-
clear whether they act alone or in concert and whether individual
proteins are restricted to specific injury and disease conditions.
We report that lack of Cr2 in mice leads to a twofold to three-
fold increase in the number of immature neuroblasts (Fig. 4) and
an40% increase inmature neurons (Fig. 6C) in the young adult
hippocampus, suggesting CR2/CD35 may have a physiological
role in the control of NPCnumber in the adultmouse by exerting
a tonic inhibitory signal. In support of this, lineage tracing studies
using a Cr2-cre-controlled reporter gene indicate that Cr2 is ex-
pressed in a small set of cells in the subgranular layer of the
dentate gyrus that show neural stem cell-like characteristics ex-
pressing Sox2 (Fig. 1). Lack of Cr2may also lead to an expansion
of such early, possibly uncommitted cells, but more studies are
needed to prove this point. Low-level Cr2 reporter gene expres-
sion was also noted in dentate gyrus granule neurons, and very
low levels of Cr2 transcripts were detected in primary astrocytes
(Fig. 2D). CR2 expression had previously been documented in
human glioma cells and fetal astrocytes (Gasque et al., 1996), but
its expression in mice seems much lower.
We do not know how Cr2 deficiency causes the observed in-
crease in neurogenesis and which splice form of the Cr2 gene
mediates this effect. Mouse CD35 and CR2 are spliced from the
same gene, and no conditions have been reported to favor splic-
ing of one or the other product, suggesting both isoforms are
expressed on NPCs similar to their coexpression on B-cells (Ja-
Figure 6. Number of newly generatedmature neurons is increased in Cr2/mice. After a
long-term labeling protocol, 8-week-old Cr2/mice andwild-type littermate controls (n
8 mice per group) were injected once with BrdU and killed 28 d later. A, The total number of
BrdU cells was increased in Cr2/ mice at 8 weeks and at 5–7 months of age. B, Repre-
sentative confocal microscopy image from the granular cell layer of the dentate gyrus from a
brain section immunostained for BrdU (red) andNeuN (blue). Scale bar, 20m.C, Total number
of BrdU/NeuN mature neurons was increased in Cr2/ mice at 8 weeks of age. Bars
represent mean SEM. *p 0.05, by t test.
Figure 7. Acute C3d administration reduces the number of BrdU neuroblasts inwild-type
but not Cr2/ littermate control mice. Four-month-old Cr2/ mice and wild-type litter-
mate controls (n4mice per group)were given intracerebral injections of purified humanC3d
(0.5g in 0.5l) and an equal volume of saline into the right and left dentate gyrus, respec-
tively. BrdU was injected once daily until mice were killed 7 d later. A, Representative confocal
image of the C3d-injected (right) and saline-injected (left) dentate gyrus (DG) from a single
coronal brain section of a wild-type and Cr2/ mouse double stained for Dcx (green) and
BrdU (red). Scale bars, 50m. B, Average number of BrdU/Dcx cells per brain section for
four individualmice per genotype. Connected dots represent the averagenumber of cells on the
saline- and C3d-injected side of each mouse. Note the reduction in cell number on the C3d-
injected site in wild-type but not in Cr2/ mice. C, Calculation of the ratio of the average
number of BrdU/Dcx cells on the C3d-injected compared with the saline-injected side in
wild-type (WT) compared with Cr2/ mice. Bars represent mean  SD. *p  0.05, by
Student’s t test.
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cobson andWeis, 2008). Furthermore, it is predicted that mouse
CR2 ligands would also bind to mouse CD35, making it difficult
to exclude a role for CD35 in the observed effects (Molina et al.,
1994). Additional studies will also be necessary to address
whether CR2 on NPCs forms a similar signaling complex as the
one found in B-cells with CD19, CD81, and CD225. Notably, all
three genes seem to be expressed in NPCs (supplemental Fig. S1,
available at www.jneurosci.org as supplemental material).
Based on our results in CR2/CD35-deficient mice, physiolog-
ical levels of endogenous ligands may function to control basal
neurogenesis, whereas increased levels of complement C3d or
IFN- after injury may lead to detrimental inhibition of neuro-
genesis. Human CR2 is the main receptor for C3d; it is also a
receptor for IFN- (although IFN- signals through classical
IFN- receptors as well), CD23, and the Epstein-Barr virus enve-
lope protein gp350 (Asokan et al., 2006). Interestingly, basal neu-
rogenesis in the dentate gyrus was significantly reduced not only
in C3aR knock-outmice but also in C3 knock-outmice (Rahpey-
mai et al., 2006), which cannot generate the C3 cleavage product
C3a. Because C3d is also derived from C3, we would expect neu-
rogenesis to increase in C3 knock-out mice if C3d signaling was
actively suppressing neurogenesis via Cr2. We therefore think
C3d is not responsible for suppressing neurogenesis via Cr2 un-
der physiological conditions. Nevertheless, C3d appears to be
sufficient to reduce the number of immature neuroblasts in vivo
(Fig. 7) andmay exert such a function after CNS injury.We think
it is more likely that CR2 ligands exert their effect by reducing
proliferation of neuroblasts rather than by increasing apoptosis
because we were unable to detect an increase in activated caspase
staining in vivo, although the methods successfully detected
alcohol-induced cell death (data not shown). With respect to
IFN-, at least 13 functional subtypes have been described in
humans (Theofilopoulos et al., 2005), and it is unclear whether
they are constitutively produced at levels that might trigger CR2
signaling in NPCs in the normal brain and whether they differ in
their affinity for CR2. Evenwithout knowing the key endogenous
ligand, therapeutic inhibition of CR2 signaling may promote
basal neurogenesis in aging or restore neurogenesis in a number
of inflammatory conditionswhere C3d or IFN- are elevated and
neurogenesis is reduced.
Adult hippocampal neurogenesis is being linked ever more
strongly to the formation of specific new memories in rodents
(Dupret et al., 2008; Zhang et al., 2008), and it is possible that
neurogenesis in the human hippocampusmay have a similar role
(Leuner et al., 2006; Zhao et al., 2008). Although this issue is far
frombeing settled, our findingsmay shednew light on an intrigu-
ing association of increased levels of C3d or IFN- with memory
problems or neuropsychiatric conditions in several human dis-
eases. For example, C3d levels are increased in human immuno-
deficiency virus (HIV) (Fust et al., 1991), and increased levels of
IFN- in the CSF have been linked with HIV dementia (Rho et
al., 1995). Similarly, C3d (Rother et al., 1993) and IFN- (Harri-
son and Ravdin, 2002; Schmidt and Ouyang, 2004) levels are
increased in autoimmune diseases such as systemic lupus ery-
thematosus, which frequently presents with cognitive impair-
ment. Perhaps the strongest evidence for a possible link between
IFN- and cognition comes from patients treated with recombi-
nant IFN- as part of a therapy for hepatitis C virus infection or
cancer (Pavol et al., 1995; Scheibel et al., 2004; Hilsabeck et al.,
2005). At least one-third of patients have been reported to de-
velop depression or cognitive deficits linked to the treatment, and
normal function is regained after treatment is discontinued.
Consistent with these observations in humans, adult rats treated
with IFN- showed depression-like symptoms and reduced cell
proliferation (BrdU incorporation) in the dentate gyrus (Kaneko
et al., 2006). Although these authors had no mechanistic expla-
nation of their findings, our study suggests that the observed
effects of IFN- in rats and possibly in humans could bemediated
through CR2 expressed on NPCs. Together with published stud-
ies, our findings support a scenario in which abnormal CR2 sig-
naling in certain viral infections and autoimmune disorders
inhibits neurogenesis and, as a result, leads to depressive symp-
toms and cognitive impairments.
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